ReviewTherapeutics and clinical risk management2016
Concentrated insulins: the new basal insulins.
Review in Therapeutics and clinical risk management, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it, 53 citations in OpenAlex.
- [Diagnostics and treatment of type 1 diabetes mellitus (Update 2026)].Wiener klinische Wochenschrift · 2026Guideline
- Timing of Insulin Glargine 300 U/ML: Does It Really Matter in Terms of Efficacy and Safety at Insulin Initiation?Cureus · 2025Article
- Once-weekly Insulin Icodec Versus Once-daily Long-acting Insulin for Type II Diabetes: A Meta-analysis of Randomized Controlled Trials.Journal of the Endocrine Society · 2024Review
- Factors Affecting Performance of Insulin Pen Injector Technology: A Narrative Review.Journal of diabetes science and technology · 2023Review
- [Injection therapy of diabetes].Wiener klinische Wochenschrift · 2023Article
- [Diagnosis and insulin therapy of type 1 diabetes mellitus (Update 2023)].Wiener klinische Wochenschrift · 2023Article
- Severe insulin resistance syndromes.The Journal of clinical investigation · 2021Review
- Glargine-300: An updated literature review on randomized controlled trials and real-world studies.World journal of diabetes · 2020Review
- Effect of Different Insulin Therapies on Obstetric-Fetal Outcomes.Scientific reports · 2019Article
- [Diagnosis and insulin therapy of type 1 diabetes mellitus (Update 2019)].Wiener klinische Wochenschrift · 2019Review
- [Insulin therapy of type 2 diabetes mellitus (Update 2019)].Wiener klinische Wochenschrift · 2019Review
- Insulin Initiation and Titration in Patients With Type 2 Diabetes.Diabetes spectrum : a publication of the American Diabetes Association · 2019Article
- Basal insulin therapy: Unmet medical needs in Asia and the new insulin glargine in diabetes treatment.Journal of diabetes investigation · 2019Review
- Nocturnal Glycemic Control with New Insulin Glargine 300 U/mL.Advances in medicine · 2019Article
- Basal insulin reductions in anticipation of multiple exercise sessions in people with type 1 diabetes-a clinical perspective.Annals of translational medicine · 2018Article
- Conversion from insulin glargine U-100 to insulin glargine U-300 or insulin degludec and the impact on dosage requirements.Therapeutic advances in endocrinology and metabolism · 2018Article
- Factors Affecting the Absorption of Subcutaneously Administered Insulin: Effect on Variability.Journal of diabetes research · 2018Review
- Translating U-500R Randomized Clinical Trial Evidence to the Practice Setting: A Diabetes Educator/Expert Prescriber Team Approach.The Diabetes educator · 2017Article
- Novel Concentrated Insulin Delivery Devices: Developments for Safe and Simple Dose Conversions.Journal of diabetes science and technology · 2017Review
- Microfabrication for Drug Delivery.Materials (Basel, Switzerland) · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionInsulin therapy plays a critical role in the treatment of type 1 and type 2 diabetes mellitus. However, there is still a need to find basal insulins with 24-hour coverage and reduced risk of hypoglycemia. Additionally, with increasing obesity and insulin resistance, the ability to provide clinically necessary high doses of insulin at low volume is also needed. AREAS COVERED: This review highlights the published reports of the pharmacokinetic (PK) and glucodynamic properties of concentrated insulins: Humulin-R U500, insulin degludec U200, and insulin glargine U300, describes the clinical efficacy, risk of hypoglycemic, and metabolic changes observed, and finally, discusses observations about the complexity of introducing a new generation of concentrated insulins to the therapeutic market.
conclusionHumulin-R U500 has a similar onset but longer duration of action compared with U100 regular insulin. Insulin glargine U300 has differential PK/pharmacodynamic effects when compared with insulin glargine U100. In noninferiority studies, glycemic control with degludec U200 and glargine U300 is similar to insulin glargine U100 and nocturnal hypoglycemia is reduced. Concentrated formulations appear to behave as separate molecular entities when compared with earlier U100 insulin analog compounds. In the review of available published data, newer concentrated basal insulins may offer an advantage in terms of reduced intraindividual variability as well as reducing the injection burden in individuals requiring high-dose and large volume insulin therapy. Understanding the PK and pharmacodynamic properties of this new generation of insulins is critical to safe dosing, dispensing, and administration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.